Cynvenio's LiquidBiopsy platform is designed to extract and isolate circulating tumor cells from a blood draw and prepare them for imaging and genomic analysis.
CEO Jay Flatley preannounced fourth-quarter revenues of $512 million and also unveiled the HiSeq X Five System, the HiSeq 3000 and 4000 Systems, and the NextSeq 550 System, an NGS system enabled for array scanning.
The partners hope to detect EGFR mutations in lung cancer patients using Trovagene's Precision Cancer Monitoring platform.
The assay analyzes circulating nucleic acids in blood samples to detect EGFR mutations in non-small cell lung cancer.
Exosome will use the ALCMI samples to support the validation of its ALK and EGFR T790M liquid biopsy tests, which the company plans to launch this year as LDTs.
Epic will now be able to participate in additional therapeutic clinical trials as a companion diagnostic partner.
The non-invasive, blood-based circulating tumor cell and circulating tumor DNA cancer tests will be made available to 19 million patients.
In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.
Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.